Norman J. Lacayo, MD

Publications

• AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. Rosen DB, Harrington KH, Cordeiro JA, Leung LY, Putta S, Lacayo N, Laszlo GS, Gudgeon CJ, Hogge DE, Hawtin RE, Cesano A, Walter RB. PLoS One. 2013; 8 (1): e53518
• Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group. Lacayo NJ, Alonzo TA, Gayko U, Rosen DB, Westfall M, Purvis N, Putta S, Louie B, Hackett J, Cohen AC, Cesano A, Gerbing R, Ravindranath Y, Dahl GV, Gamis A, Meshinchi S. Br J Haematol. 2013
• Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children's Oncology Group Study POG 9421. O'Brien MM, Cao X, Pounds S, Dahl GV, Raimondi SC, Lacayo NJ, Taub J, Chang M, Weinstein HJ, Ravindranath Y, Inaba H, Campana D, Pui CH, Rubnitz JE. Leukemia. 2013; 27 (3): 731-4
• Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML. Rosen DB, Cordeiro JA, Cohen A, Lacayo N, Hogge D, Hawtin RE, Cesano A. Leuk Res. 2012; 36 (7): 900-4
• Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO. PLoS One. 2012; 7 (2): e30733
• Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. Gawad C, Pepin F, Carlton VE, Klinger M, Logan AC, Miklos DB, Faham M, Dahl G, Lacayo N. Blood. 2012; 120 (22): 4407-17
• A pilot study of an online cognitive rehabilitation program for executive function skills in children with cancer-related brain injury. Kesler SR, Lacayo NJ, Jo B. Brain Inj. 2011; 25 (1): 101-12
• Dorsolateral midbrain MRI abnormalities and ocular motor deficits following cytarabine-based chemotherapy for acute myelogenous leukemia. Doan T, Lacayo N, Fisher PG, Liao YJ. J Neuroophthalmol. 2011; 31 (1): 52-3
• Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X, Meshinchi S, Degar B, Airewele G, Raimondi SC, Onciu M, Coustan-Smith E, Downing JR, Leung W, Pui CH, Campana D. Lancet Oncol. 2010; 11 (6): 543-52
• Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group. O'Brien MM, Lacayo NJ, Lum BL, Kshirsagar S, Buck S, Ravindranath Y, Bernstein M, Weinstein H, Chang MN, Arceci RJ, Sikic BI, Dahl GV. Pediatr Blood Cancer. 2010; 54 (5): 694-702
• Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, Dahl G, Lacayo NJ, Becton D, Chang M, Weinstein HJ, Hirsch B, Raimondi SC, Heerema NA, Woods WG, Lange BJ, Hurwitz C, Arceci RJ, Radich JP, Bernstein ID, Heinrich MC, Meshinchi S. Blood. 2010; 115 (12): 2372-9
• Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia. Schiffman JD, Wang Y, McPherson LA, Welch K, Zhang N, Davis R, Lacayo NJ, Dahl GV, Faham M, Ford JM, Ji HP. Cancer Genet Cytogenet. 2009; 193 (1): 9-18
• Speeding the flow toward personalized therapy in childhood acute leukemia. Simonds EF, Davis KL, Lacayo NJ. Pediatr Blood Cancer. 2009; 53 (4): 525-6
• WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children's Oncology Group. Noronha SA, Farrar JE, Alonzo TA, Gerbing RB, Lacayo NJ, Dahl GV, Ravindranath Y, Arceci RJ, Loeb DM. Pediatr Blood Cancer. 2009; 53 (6): 1136-9
• Tissue microarrays from bone marrow aspirates for high-throughput assessment of immunohistologic markers in pediatric acute leukemia. Hazard FK, Zhao S, Schiffman JD, Lacayo NJ, Dahl GV, Natkunam Y. Pediatr Dev Pathol. 2008 Jul-Aug; 11 (4): 283-90
• Acute leukemia in children. O'Brien MM, Lacayo NJ. Dis Mon. 2008; 54 (4): 202-25
• Genomics of childhood leukemias: the virtue of complexity. Sikic BI, Tibshirani R, Lacayo NJ. J Clin Oncol. 2008; 26 (27): 4367-8
• Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. Juric D, Lacayo NJ, Ramsey MC, Racevskis J, Wiernik PH, Rowe JM, Goldstone AH, O'Dwyer PJ, Paietta E, Sikic BI. J Clin Oncol. 2007; 25 (11): 1341-9
• The incidence and clinical significance of nucleophosmin mutations in childhood AML. Brown P, McIntyre E, Rau R, Meshinchi S, Lacayo N, Dahl G, Alonzo TA, Chang M, Arceci RJ, Small D. Blood. 2007; 110 (3): 979-85
• CpG island methylator phenotype and childhood leukemia. Lacayo NJ, DiMartino JF, Wei MC, Dahl GV. Clin Cancer Res. 2006; 12 (16): 4787-9
• Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. DiMartino JF, Lacayo NJ, Varadi M, Li L, Saraiya C, Ravindranath Y, Yu R, Sikic BI, Raimondi SC, Dahl GV. Leukemia. 2006; 20 (3): 426-32
• Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC, Head DR, Stine KC, Lacayo NJ, Sikic BI, Arceci RJ, Weinstein H. Blood. 2006; 107 (4): 1315-24
• Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Lacayo NJ, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM, Douglas L, Wahab R, Becton DL, Weinstein H, Chang MN, Willman CL, Radich JP, Tibshirani R, Ravindranath Y, Sikic BI, Dahl GV. Blood. 2004; 104 (9): 2646-54
• Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells. Lacayo NJ, Duran GE, Sikic BI. J Exp Ther Oncol. 2003 May-Jun; 3 (3): 127-35
• Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Lacayo NJ, Lum BL, Becton DL, Weinstein H, Ravindranath Y, Chang MN, Bomgaars L, Lauer SJ, Sikic BI, Dahl GV. Leukemia. 2002; 16 (5): 920-7
• Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma. Chen GK, Lacayo NJ, Durán GE, Wang Y, Bangs CD, Rea S, Kovacs M, Cherry AM, Brown JM, Sikic BI. Genes Chromosomes Cancer. 2002; 34 (4): 372-83
• Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant P-glycoprotein with deleted phe(335). Chen GK, Lacayo NJ, Durán GE, Cohen D, Sikic BI. Mol Pharmacol. 2000; 57 (4): 769-77
• Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. Dahl GV, Lacayo NJ, Brophy N, Dunussi-Joannopoulos K, Weinstein HJ, Chang M, Sikic BI, Arceci RJ. J Clin Oncol. 2000; 18 (9): 1867-75
• Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. Chen G, Durán GE, Steger KA, Lacayo NJ, Jaffrézou JP, Dumontet C, Sikic BI. J Biol Chem. 1997; 272 (9): 5974-82